|
시장보고서
상품코드
2032446
건선성 관절염 치료 시장 보고서 : 약제 유형, 질환 유형, 투여 경로, 유통 채널 및 지역별(2026-2034년)Psoriatic Arthritis Treatment Market Report by Drug Type (NSAIDs, DMARDs, Biologics, and Others), Type, Route of Administration, Distribution Channel, and Region 2026-2034 |
||||||
세계의 건선성 관절염 치료 시장 규모는 2025년에 115억 달러에 이르렀습니다. 향후 IMARC Group은 2034년까지 시장 규모가 241억 달러에 이르고, 2026-2034년 CAGR 8.36%를 나타낼 것으로 예측했습니다.
건선성 관절염은 면역체계가 관절을 공격해 염증을 일으키는 자가면역질환입니다. 치료법은 부종과 염증을 억제하는 경구용 약물부터 특정 면역 체계를 표적으로 하는 생물학적 제제까지 다양합니다. 치료는 통증, 부종, 뻣뻣함의 정도에 따라 이루어집니다. 현재 주요 기업들은 질병의 진행을 예방하고, 통증을 줄이고, 관절을 보호하고, 운동 범위를 유지하는 데 도움이 되는 새로운 치료법을 도입하고 있습니다. 이러한 방법은 근육과 관절을 강화하고 전반적인 안정성을 높이기 위해 물리치료와 결합할 수 있습니다.
건선성 관절염 치료 시장 동향 :
건선은 건선성 관절염의 주요 위험 요인 중 하나입니다. 그 결과, 감염, 스트레스, 비만, 피부 손상, 알코올 남용, 비타민 결핍으로 인한 건선 유병률 증가는 시장에 긍정적인 영향을 미치는 주요 요인 중 하나입니다. 또한, 건선성 관절염은 30세에서 50세 사이에 가장 많이 발생하기 때문에 전 세계 성인 인구 증가가 시장 성장에 기여하고 있습니다. 이와는 별도로 건선성 관절염을 앓고 있는 어린이는 안구 벽의 중간층에 영향을 미치는 포도막염이 발생할 위험이 높습니다. 이러한 사실에 더해 자녀의 건강에 대한 부모들의 관심이 높아지면서 전 세계적으로 건선성 관절염 치료에 대한 수요가 증가하고 있습니다. 또한, 중증 장애 예방 등 건선성 관절염의 조기 진단 및 치료의 이점에 대한 인식이 높아짐에 따라 시장 성장에 힘을 보태고 있습니다. 개인의 가처분 소득 증가, 의료시설의 개선, 개인의 건강 의식 향상 등 다른 요인들도 심각한 증상에 대처하기 위한 새로운 건선성 관절염 치료에 대한 수요를 견인할 것으로 예측됩니다.
본 보고서에서 답변을 얻을 수 있는 주요 질문
- 지금까지의 세계 건선성 관절염 치료 시장 동향은 어떠했으며, 향후 몇 년 동안 어떻게 변화할 것인가?
- COVID-19는 세계 건선성 관절염 치료 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은?
- 약품 유형별 시장 현황은?
- 시장 유형별 시장 분석은?
- 투여 경로별 시장 현황은?
- 유통 채널별 시장 현황은?
- 이 산업의 밸류체인에서 각 단계는?
- 이 산업의 주요 촉진요인과 과제는?
- 세계 건선성 관절염 치료 시장의 구조는 무엇이며, 주요 기업은?
- 이 업계의 경쟁은 얼마나 치열한가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 건선성 관절염 치료 시장
제6장 시장 분석 : 약제 유형별
제7장 시장 분석 : 유형별
제8장 시장 분석 : 투여 경로별
제9장 시장 분석 : 유통 채널별
제10장 시장 분석 : 지역별
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
JHS 26.05.18The global psoriatic arthritis treatment market size reached USD 11.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 24.1 Billion by 2034, exhibiting a growth rate (CAGR) of 8.36% during 2026-2034.
Psoriatic arthritis is an autoimmune disorder wherein the immune system attacks the joints and causes inflammation. Its treatment options vary from oral medications that reduce swelling and inflammation to biological therapies that target the specific immune system. It is treated as per the level of pain, swelling, and stiffness. At present, key players are introducing new treatment methods that help prevent disease progression, reduce pain, protect joints, and preserve the range of motion. These methods can be combined with physical therapy to strengthen muscles and joints and increase overall stability.
PSORIATIC ARTHRITIS TREATMENT MARKET TRENDS:
Psoriasis disease is one of the major risk factors for psoriatic arthritis. As a result, the increasing prevalence of psoriasis disease due to infection, stress, obesity, skin injuries, alcohol abuse, and vitamin deficiencies represents one of the primary factors influencing the market positively. Moreover, as psoriatic arthritis occurs most commonly among individuals between the ages of 30 and 50, the rising adult population worldwide is contributing to the market growth. Apart from this, children with psoriatic arthritis are more likely to develop uveitis that affects the middle layer of tissue in the eyewall. This, in confluence with the growing concerns among parents about the health of their children, is catalyzing the demand for psoriatic arthritis treatment across the globe. In addition, the rising awareness about the benefits of early diagnosis and treatment of psoriatic arthritis, such as preventing serious damages, is bolstering the market growth. Other factors, such as inflating disposable income of individuals, improvement in healthcare facilities, and the growing health awareness among individuals, are anticipated to drive the demand for novel psoriatic arthritis treatment to combat severe symptoms.
KEY MARKET SEGMENTATION:
Breakup by Drug Type:
- NSAIDs (Nonsteroidal Anti-Inflammatory drugs)
- DMARDs (Disease-Modifying Anti-Rheumatic Drugs)
- Biologics
- Others
Breakup by Type:
- Prescription
- OTC
Breakup by Route of Administration :
- Injectable
- Oral
- Topical
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals LLC, AstraZeneca plc, Bristol-Myers Squibb Company, Eisai Co. Ltd., Eli Lilly and Company, Johnson & Johnson Service ltd., Novartis AG, Pfizer Inc., Samsung Biologics and UCB S.A.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global psoriatic arthritis treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global psoriatic arthritis treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global psoriatic arthritis treatment market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Psoriatic Arthritis Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Drug Type
- 6.1 NSAIDs (Nonsteroidal Anti-Inflammatory Drugs)
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 DMARDs (Disease-Modifying Anti-Rheumatic Drugs)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Biologics
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Type
- 7.1 Prescription
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 OTC
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Route of Administration
- 8.1 Injectable
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Oral
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Topical
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Distribution Channel
- 9.1 Hospital Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Online Pharmacies
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 AbbVie Inc.
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Amgen Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Amneal Pharmaceuticals LLC
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.4 AstraZeneca plc
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 Bristol-Myers Squibb Company
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 Eisai Co. Ltd.
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Eli Lilly and Company
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Johnson & Johnson Service ltd.
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Novartis AG
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Pfizer Inc.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Samsung Biologics
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.12 UCB S.A.
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
- 15.3.12.4 SWOT Analysis
- 15.3.1 AbbVie Inc.
